Ileo-cecal targeting mucoadhesive budesonide tablet
Crohn's disease occurs at any part of gastro-intestinal tract (GIT) but the most susceptible is the ileo-cecal region. For an effective treatment of this disease is essential the drug to be released at ileo-cecal region for an extended period of time. The present study is an attempt to design...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Articulo |
| Lenguaje: | Inglés |
| Publicado: |
2010
|
| Materias: | |
| Acceso en línea: | http://sedici.unlp.edu.ar/handle/10915/8002 http://www.latamjpharm.org/resumenes/29/6/LAJOP_29_6_1_7.pdf |
| Aporte de: |
| Sumario: | Crohn's disease occurs at any part of gastro-intestinal tract (GIT) but the most susceptible is
the ileo-cecal region. For an effective treatment of this disease is essential the drug to be released at ileo-cecal
region for an extended period of time. The present study is an attempt to design and develop an ileo-cecal
targeting mucoadhesive drug delivery system that may be released specifically and slowly in ileo-cecal
region without being released in the upper GIT for an extended period of time (12 h). Budesonide mucoadhesive
tablets are coated with Eudragit S100, which is a polymer that specifically dissolves at and above
pH 6.8. The in vitro drug release by changing pH method was done and in vivo study using X-ray radiography
was carried out to ascertain the position of tablets in GIT after specific time intervals. The in vitro
performance of the tablet with 10 % w/w coating level showed that the tablet did not disintegrate till 16 h
with constant drug release. An in vivo study also reveals that the tablet lasted till 16 h in the ileo-cecal region. |
|---|